Bank of New York Mellon’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Bank of New York Mellon’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-26,335	Closed	-$7K	–	4438
2018 Q1	$7K	Buy	+26,335	New	+$7.27K	﹤0.01%	4301
2017 Q4	–	Sell	-25,029	Closed	-$10K	–	4493
2017 Q3	$10K	Buy	+25,029	New	+$12.2K	﹤0.01%	4243
2016 Q4	–	Sell	-2,259	Closed	-$10K	–	4400
2016 Q3	$10K	Sell	2,259 -863	-28%	-$5.55K	﹤0.01%	4250
2016 Q2	$28K	Buy	3,122 +588	+23%	+$6.05K	﹤0.01%	4247
2016 Q1	$29K	Hold	2,534	–	–	﹤0.01%	4149
2015 Q4	$36K	Hold	2,534	–	–	﹤0.01%	4227
2015 Q3	$43K	Hold	2,534	–	–	﹤0.01%	4263
2015 Q2	$48K	Buy	2,534 +234	+10%	+$4.5K	﹤0.01%	4167
2015 Q1	$45K	Hold	2,300	–	–	﹤0.01%	4151
2014 Q4	$67K	Hold	2,300	–	–	﹤0.01%	4123
2014 Q3	$82K	Hold	2,300	–	–	﹤0.01%	4094
2014 Q2	$103K	Buy	2,300 +11	+0.5%	+$531	﹤0.01%	3986
2014 Q1	$112K	Hold	2,289	–	–	﹤0.01%	3964
2013 Q4	$85K	Hold	2,289	–	–	﹤0.01%	4048
2013 Q3	$235K	Hold	2,289	–	–	﹤0.01%	3755
2013 Q2	$178K	Buy	+2,289	New	+$219K	﹤0.01%	3798

Other funds holding IMUC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FAAS

First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RCAG

Rehmann Capital Advisory Group Lansing, Michigan $1.92B AUM 16.97% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Bank of New York Mellon's IMUC Position: Q2 2018 in Review

Bank of New York Mellon sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q2 2018, closing a stake of 26,335 shares — an estimated $7K sold.

Bank of New York Mellon first reported a position in IMUC in Q2 2013 and held it in 16 quarters. The position peaked at $235K in Q3 2013. 20 funds tracked by Wall St. Rank hold IMUC as of Q2 2018.

Bank of New York Mellon reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q2 2018 after selling out during the quarter.
Bank of New York Mellon sold 26,335 ImmunoCellular Therapeutics, Ltd. shares in Q2 2018, an estimated $7K.
Bank of New York Mellon first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 16 quarters.
Bank of New York Mellon's ImmunoCellular Therapeutics, Ltd. position peaked at $235K in Q3 2013.
20 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q2 2018.

Based on Bank of New York Mellon's 13F filing for Q2 2018, filed 6 Aug 2018.